MedTrace Logo

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

NCT02787369 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-05-19

No results posted yet for this study

Summary

This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Conditions

  • Recurrent Chronic Lymphoid Leukemia

Interventions

DRUG

ACY-1215

DRUG

Ibrutinib

DRUG

Idelalisib

Sponsors & Collaborators

Principal Investigators

  • Jennifer B Brown, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2026-04-30
Completion
2027-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02787369 on ClinicalTrials.gov